CH695662A5 - Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn. - Google Patents

Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn. Download PDF

Info

Publication number: CH695662A5
Authority: CH; Switzerland
Prior art keywords: sep; brivudine; treatment; magnesium stearate; microcrystalline cellulose
Prior art date: 2001-01-03

Application number

CH00987/01A

Other languages

German (de)

English (en)

Inventor

Attilo Crea

Bettina Stubinski

Alessandro Casini

Original Assignee

Menarini Ricerche Spa

Berlin Chemie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-03

Filing date

2001-05-29

Publication date

2006-07-31

2001-05-29 Application filed by Menarini Ricerche Spa, Berlin Chemie Ag filed Critical Menarini Ricerche Spa

2006-07-31 Publication of CH695662A5 publication Critical patent/CH695662A5/de

Links

ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title claims description 91
229960001169 brivudine Drugs 0.000 title claims description 86
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
238000011282 treatment Methods 0.000 claims description 55
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 27
208000007514 Herpes zoster Diseases 0.000 claims description 23
235000019359 magnesium stearate Nutrition 0.000 claims description 18
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
239000008108 microcrystalline cellulose Substances 0.000 claims description 17
239000008213 purified water Substances 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
208000015181 infectious disease Diseases 0.000 claims description 9
229910002012 Aerosil® Inorganic materials 0.000 claims description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
229920001531 copovidone Polymers 0.000 claims description 6
239000008101 lactose Substances 0.000 claims description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
229940069328 povidone Drugs 0.000 claims description 6
229920002261 Corn starch Polymers 0.000 claims description 4
239000008120 corn starch Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
229960003511 macrogol Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 4
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
229960001375 lactose Drugs 0.000 claims 2
229960001021 lactose monohydrate Drugs 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000004408 titanium dioxide Substances 0.000 claims 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 41
229960004150 aciclovir Drugs 0.000 description 37
208000002193 Pain Diseases 0.000 description 11
230000001154 acute effect Effects 0.000 description 7
241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
229940086177 acyclovir 800 mg Drugs 0.000 description 5
241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
206010039509 Scab Diseases 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
229960004396 famciclovir Drugs 0.000 description 4
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 4
208000010201 Exanthema Diseases 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
201000005884 exanthem Diseases 0.000 description 3
239000012729 immediate-release (IR) formulation Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
206010037844 rash Diseases 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229940093257 valacyclovir Drugs 0.000 description 3
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229960001179 penciclovir Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
206010040882 skin lesion Diseases 0.000 description 2
231100000444 skin lesion Toxicity 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000012410 herpes zoster dermatitis Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000001790 virustatic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CH00987/01A 2001-01-03 2001-05-29 Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn. CH695662A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001MI000009A ITMI20010009A1 (it)	2001-01-03	2001-01-03	Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera

Publications (1)

Publication Number	Publication Date
CH695662A5 true CH695662A5 (de)	2006-07-31

Family

ID=11446384

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH00987/01A CH695662A5 (de)	2001-01-03	2001-05-29	Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn.

Country Status (20)

Country	Link
AT (1)	AT6141U1 (fr)
BE (1)	BE1014522A5 (fr)
CH (1)	CH695662A5 (fr)
CZ (1)	CZ20012464A3 (fr)
DK (1)	DK177084B1 (fr)
ES (1)	ES2192456B1 (fr)
FI (1)	FI20011446A7 (fr)
FR (1)	FR2818907B1 (fr)
GB (1)	GB2370771A (fr)
GR (1)	GR1004012B (fr)
HR (1)	HRPK20010345B3 (fr)
HU (1)	HUP0102816A3 (fr)
IE (1)	IE20010413A1 (fr)
IT (1)	ITMI20010009A1 (fr)
NL (1)	NL1018431C2 (fr)
PL (1)	PL348480A1 (fr)
PT (1)	PT102642B (fr)
SE (1)	SE0102309L (fr)
SK (1)	SK287043B6 (fr)
UA (1)	UA76402C2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2239527B1 (es) *	2004-03-01	2006-11-16	M. Cruz Fernandez Gonzalez	Composicion farmacologica de uso topico para el tratamiento del herpes zoster.
CN113712928A (zh) *	2021-09-29	2021-11-30	重庆市力扬医药开发有限公司	经口腔粘膜吸收的溴夫定药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0104857A1 (fr) *	1982-09-28	1984-04-04	Beecham Group Plc	Dérivés de la déoxyuridine, leurs méthodes de préparation et leur emploi en médecine
IT1170232B (it) *	1983-10-31	1987-06-03	Anna Gioia Stendardi	Composizioni terapeutiche ad attivita' antivirale
US5446031A (en) *	1991-04-24	1995-08-29	Yamasa Shuyu Kabushiki Kaisha	1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives
CA2243237C (fr) *	1996-01-19	2008-09-02	Glaxo Group Limited	Utilisation de valaciclovir dans la fabrication d'un medicament destine au traitement de l'herpes genital

2001
- 2001-01-03 IT IT2001MI000009A patent/ITMI20010009A1/it unknown
- 2001-04-25 IE IE20010413A patent/IE20010413A1/en not_active IP Right Cessation
- 2001-05-01 GB GB0110682A patent/GB2370771A/en not_active Withdrawn
- 2001-05-11 HR HR20010345A patent/HRPK20010345B3/xx not_active IP Right Cessation
- 2001-05-29 CH CH00987/01A patent/CH695662A5/de not_active IP Right Cessation
- 2001-06-28 SE SE0102309A patent/SE0102309L/ not_active Application Discontinuation
- 2001-06-29 DK DKPA200101019A patent/DK177084B1/da not_active IP Right Cessation
- 2001-06-29 FR FR0108596A patent/FR2818907B1/fr not_active Expired - Lifetime
- 2001-07-02 NL NL1018431A patent/NL1018431C2/nl not_active IP Right Cessation
- 2001-07-03 FI FI20011446A patent/FI20011446A7/fi not_active Application Discontinuation
- 2001-07-04 BE BE2001/0452A patent/BE1014522A5/fr not_active IP Right Cessation
- 2001-07-04 CZ CZ20012464A patent/CZ20012464A3/cs unknown
- 2001-07-04 UA UA2001074658A patent/UA76402C2/uk unknown
- 2001-07-04 SK SK957-2001A patent/SK287043B6/sk not_active IP Right Cessation
- 2001-07-05 HU HU0102816A patent/HUP0102816A3/hu unknown
- 2001-07-05 GR GR20010100322A patent/GR1004012B/el unknown
- 2001-07-05 PT PT102642A patent/PT102642B/pt active IP Right Grant
- 2001-07-05 ES ES200101566A patent/ES2192456B1/es not_active Expired - Fee Related
- 2001-07-05 PL PL01348480A patent/PL348480A1/xx not_active Application Discontinuation
2002
- 2002-07-03 AT AT0805702U patent/AT6141U1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI20011446L (fi)	2002-07-04
CZ20012464A3 (cs)	2002-08-14
FR2818907A1 (fr)	2002-07-05
ES2192456B1 (es)	2005-02-01
GB0110682D0 (en)	2001-06-20
HRP20010345A2 (en)	2003-08-31
IE20010413A1 (en)	2003-04-16
PL348480A1 (en)	2002-07-15
AT6141U1 (de)	2003-05-26
HRPK20010345B3 (en)	2005-02-28
FI20011446A7 (fi)	2002-07-04
ITMI20010009A1 (it)	2002-07-03
DK177084B1 (da)	2011-07-11
GR1004012B (el)	2002-11-01
FI20011446A0 (fi)	2001-07-03
GR20010100322A (el)	2002-10-08
FR2818907B1 (fr)	2006-05-26
DK200101019A (da)	2002-07-04
SK9572001A3 (en)	2003-03-04
HUP0102816A3 (en)	2005-01-28
ITMI20010009A0 (it)	2001-01-03
UA76402C2 (en)	2006-08-15
HU0102816D0 (en)	2001-09-28
PT102642A (pt)	2002-07-31
BE1014522A5 (fr)	2003-12-02
ES2192456A1 (es)	2003-10-01
SK287043B6 (sk)	2009-10-07
NL1018431C2 (nl)	2002-07-05
GB2370771A (en)	2002-07-10
PT102642B (pt)	2003-06-30
HUP0102816A2 (en)	2002-10-28
SE0102309D0 (sv)	2001-06-28
SE0102309L (sv)	2002-07-04

Legal Events

Date	Code	Title	Description
2021-05-31	PL	Patent ceased

Publication	Publication Date	Title
DE69710390T2 (de)	2002-08-14	Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren
DE69922964T2 (de)	2005-12-08	Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
DE69400799T2 (de)	1997-03-13	Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60115870T3 (de)	2010-07-29	Niedrig dosierte entecavir-formulierung und deren verwendung
DE69430440T2 (de)	2002-11-14	Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
DE69513254T2 (de)	2000-06-15	Gepirone enthaltende Zusammensetzungen
WO2000037078A1 (fr)	2000-06-29	Association de cerivastatine et de fibrates
DE69420776T2 (de)	2000-05-18	Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE60017281T2 (de)	2005-12-08	Nomegestrolacetat und östrogen enthaltende Hormonzusammensetzung und ihre Verwendung
DE602004005734T2 (de)	2007-12-27	Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
EP1001756B1 (fr)	2004-04-07	Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
CH695662A5 (de)	2006-07-31	Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn.
DE69625210T2 (de)	2003-08-14	Nicorandil gegen angstneurosen
EP2374461B1 (fr)	2016-10-26	Piroxicam pour traitement prophylactique et thérapeutique d'infections de type Herpès
DE69424679T2 (de)	2001-02-08	Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69925312T2 (de)	2006-03-09	Bupropion zur behandlung von viralen erkrankungen
WO2002007713A2 (fr)	2002-01-31	Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre
EP0508511B1 (fr)	1997-12-10	Compositions contenant du verapamil et du trandolapril
DE10130128A1 (de)	2002-07-04	Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichung
DE3780702T2 (de)	1992-12-10	Verwendung von etodolac zur senkung des blutgehalts an harnsaeure.
DE2831728C2 (de)	1982-12-23	Arzneimittel zur Behandlung von Kopfschmerzen
DE3440140C2 (de)	1993-11-25	Verwendung von Thiamphenicol gegen die Gewöhnung an zentral wirkende Analgetika
DE2532180C2 (de)	1986-12-18	Verwendung von Etozolin bei der Bekämpfung der Hypertonie
DE10136615A1 (de)	2003-02-06	Schilddrüsentherapeutika
DE2823267A1 (de)	1978-12-14	Antihypertensive praeparate